2.4.1.212	2-deoxyglucose	-	6423	
2.4.1.212	4-methylesculetin	-	34881	
2.4.1.212	4-Methylumbelliferone	changes the localization of the enzyme by preventing its association with the plasma membrane	319	
2.4.1.212	4-Methylumbelliferone	-	319	
2.4.1.212	4-Methylumbelliferone	inhibits HAS because it depletes UDPGlcUA in cells; inhibits HAS because it depletes UDPGlcUA in cells; inhibits HAS because it depletes UDPGlcUA in cells	319	
2.4.1.212	5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside	modulates aortic smooth muscle cell motility and adhesive properties through AMP-activated protein kinase, AMPK	6097	
2.4.1.212	AG825	ErbB2 inhibitor, blocks the heregulin-mediated HAS isozyme phosphorylation/activation; ErbB2 inhibitor, blocks the heregulin-mediated HAS isozyme phosphorylation/activation; ErbB2 inhibitor, blocks the heregulin-mediated HAS isozyme phosphorylation/activation	38150	
2.4.1.212	brefeldin A	-	5284	
2.4.1.212	ceramide	-	726	
2.4.1.212	DTNB	52% inhibition at 0.5 mM	554	
2.4.1.212	EDTA	-	21	
2.4.1.212	ethylene glycol	-	1410	
2.4.1.212	glycerol	-	135	
2.4.1.212	HAS1 siRNA	-	146778	
2.4.1.212	iodoacetamide	15% inhibition at 5 mM, biphasic inhibition	67	
2.4.1.212	iodoacetamide	13% inhibition at 5 mM, biphasic inhibition	67	
2.4.1.212	mannose	inhibits HAS because it depletes UDP-GlcNAc in cells; inhibits HAS because it depletes UDP-GlcNAc in cells; inhibits HAS because it depletes UDP-GlcNAc in cells	988	
2.4.1.212	metformin	modulates aortic smooth muscle cell motility and adhesive properties through AMP-activated protein kinase, AMPK	3021	
2.4.1.212	methylmethanethiosulfonate	93% reduced activity at 0.05 mM	20380	
2.4.1.212	methylmethanethiosulfonate	89% reduced activity at 0.05 mM	20380	
2.4.1.212	additional information	interleukin-1beta augmented the expression of all 3 isozymes in the uterine cervix of pregnant mice, progesterone inhibited expression of isozymes HAS1 and HAS2	2	
2.4.1.212	additional information	enzyme is more active in 25 mM phosphate buffer than in 50 mM, enzyme is inhibited by increasing viscosity via addition of PEG, glycerol, sucrose or ethylene glycol	2	
2.4.1.212	additional information	using inhibitors for MEK1/2, U0126, and for PI3K, LY294002, and the SN50 inhibitor, a complete inhibition of HAS2 transcriptional activity and hyaluronan sythesis is observed	2	
2.4.1.212	additional information	not inhibitory: 4-methylumbeliferone	2	
2.4.1.212	additional information	heating, oxidization or cysteine modification with N-ethylmaleimide inhibit the enzyme	2	
2.4.1.212	additional information	HA product size is decreased by increasing concentrations of glycerol	2	
2.4.1.212	additional information	AMP-activated protein kinase, AMPK, phosphorylates HAS2 at Thr110, which inhibits its enzymatic activity, and is itself inhibit by Compound C. Isoenzymes HAS1 and HAS3 are not modified by the kinase	2	
2.4.1.212	N-ethylmaleimide	-	49	
2.4.1.212	N-ethylmaleimide	reacts with the Cys residues C226, C262, and C281, but not with C367, binding of substrates UDP-N-acetyl-D-glucosamine, UDP-D-glucuronate, or of product UDP protects the enzyme from inhibition by NEM, level of inhibition of wild-type and mutant enzymes, overview	49	
2.4.1.212	N-ethylmaleimide	biphasic inhibition, about 50% reduced reaction velocity, unaltered Km-value, 70% inhibition at 5 mM	49	
2.4.1.212	N-ethylmaleimide	60% inhibition at 5 mM, biphasic inhibition	49	
2.4.1.212	N-ethylmaleimide	inhibits wild-type and mutant enzymes by about 90% at 0.2 mM, UDP-N-acetyl-D-glucosamine protects the enzyme best against inactivation by NEM compared to diverse other nucleotide compounds, overview	49	
2.4.1.212	PEG	increasing MW increases the inhibitory effect on the enzyme, overview	34904	
2.4.1.212	PEG 20000	-	23378	
2.4.1.212	siRNA	-	772	
2.4.1.212	sodium arsenite	inhibition of wild-type and mutant enzymes, no inhibition of C262 deletion mutant, overview	2419	
2.4.1.212	sodium arsenite	40% inhibition at 10 mM	2419	
2.4.1.212	sodium arsenite	46% inhibition at 10 mM	2419	
2.4.1.212	sodium salicylate	sodium salicylate is a potent suppressor of HAS1 activation	25215	
2.4.1.212	sucrose	-	55	
2.4.1.212	sulfhydryl reagents	enzyme is inhibited by sulfhydryl-modifying reagents, inhibition mode and mechanism	978	
2.4.1.212	tetramyristoyl cardiolipin	inactivating	125135	
2.4.1.212	thiazolidinedione	ERK inhibitor, blocks the heregulin-mediated HAS isozyme phosphorylation/activation; ERK inhibitor, blocks the heregulin-mediated HAS isozyme phosphorylation/activation; ERK inhibitor, blocks the heregulin-mediated HAS isozyme phosphorylation/activation	18785	
2.4.1.212	UDP	-	26	
2.4.1.212	UDP-Gal	-	1775	
2.4.1.212	UDP-GalNAc	-	550	
2.4.1.212	UDP-GalUA	-	125134	
2.4.1.212	UDP-Glc	-	7631	
2.4.1.212	UDP-glucuronate	The substrate UDP-GlcA inhibits pmHAS in concentrations above 8 mM	226	
2.4.1.212	UMP	-	133	
2.4.1.212	UMP	dead-end inhibitor	133	
2.4.1.212	UTP	-	65